viropharma incorpor pharmaceut compani develop sold drug address serious diseas treat physician specialist hospit set compani focus product develop activ virus human diseas includ caus cytomegalovirus cmv hepat c virus hcv infect purchas shire shire pay around billion compani deal final januari viropharma member nasdaq biotechnolog index sp
compani strateg relationship glaxosmithklin scheringplough sanofiaventi viropharma acquir lev pharmaceut merger
histori
viropharma incorpor found claud h nash chief execut offic mark mckinlay vice presid research develop marc collett vice presid discoveri research johanna griffin vice presid busi develop guy d diana vice presid chemistri research none founder still compani
novemb shire plc acquir viropharma billion
board director
michel de rosen chairman sinc septemb presid chief execut offic sinc august director sinc may
vincent j milano presid chief execut offic sinc march director sinc march
paul brook director sinc februari
william d claypool director sinc decemb
michael r dougherti director sinc januari
robert j glaser director sinc august
john r leon director sinc januari
howard h pien director sinc
manag team
vincent j milano presid chief execut offic
daniel b soland vice presid chief oper offic
thoma f doyl vice presid strateg initi
colin broom vice presid chief scientif offic
robert g pietrusko vice presid global regulatori affair qualiti
j peter wolf vice presid general counsel
product
market product
vancocin pulvul hcl licens eli lilli oral vancocin antibiot treatment staphylococc enterocol antibiot associ pseudomembran coliti caus clostridium difficil
pipelin
maribavir oral antivir drug candid licens glaxosmithklin prevent treatment human cytomegalovirus diseas hematopoiet stem cellbon marrow transplant patient februari viropharma announc unit state food drug administr fda grant compani fast track status maribavir
march compani announc phase ii studi maribavir demonstr prophylaxi maribavir display strong antivir activ measur statist signific reduct rate reactiv cmv recipi hematopoiet stem cellbon marrow transplant intenttotreat analysi first day transplant number subject requir preemptiv anticmv therapi statist signific reduc pvalu maribavir group compar placebo group placebo vs maribavir mg twice daili mg daili mg twice daili respect
viropharma conduct phase iii clinic studi evalu prophylact use prevent cytomegalovirus diseas recipi allogen stem cell transplant patient februari viropharma announc phase iii studi fail achiev goal show signific differ maribavir placebo reduc rate cmv diseas
fail product
oral pleconaril viropharma first compound licens sanofi pleconaril activ virus picornavirus famili viropharma first indic enterovir mening indic abandon clinic trial demonstr efficaci
viropharma submit new drug applic pleconaril fda common cold fda antivir advisori committe recommend compani fail show adequ safeti fda subsequ issu notapprov letter
novemb viropharma licens pleconaril scheringplough develop intranas formul common cold asthma exacerb scheringplough develop pipelin august scheringplough start phase ii clinic trial
refer
refer
long road ahead viropharma motley fool septemb
mcdonald lc killgor ge thompson et al emerg epidem toxin gene variant strain clostridium difficil respons outbreak unit state n engl j med
us center diseas control prevent report sever clostridium difficileassoci diseas popul previous low risk four state
lu h thoma maribavir viropharma curr opin investig drug
fleischer r laessig k safeti efficaci evalu pleconaril treatment common cold clin infect dis doi pmid
hayden fg herrington dt coat tl kim k cooper ec villano sa liu hudson pevear dc collett m mckinlay m efficaci safeti oral pleconaril treatment cold due picornavirus adult result doubleblind random placebocontrol trial clin infect dis doi pmid
extern link
viropharmacom
